ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Clinical characteristics, outcomes, and immunosuppressive strategies in sympathetic ophthalmia: real-world experience from a french tertiary center.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSympathetic ophthalmia is a rare, potentially blinding, bilateral granulomatous panuveitis that develops in the sympathizing eye following penetrating ocular trauma or intraocular surgery involving the inciting eye. Existing studies and case series focusing on IMT use in SO include patients in these studies were treated with cyclosporine or cyclophosphamide, drugs with considerable toxicity, and so do not reflect latest IMT approaches. We aimed to describe the clinical outcomes and therapeutical management of SO, in the setting of a tertiary Ophthalmology center in France.
methodsRetrospective observational single-center study: all patients with suspected SO seen between January 2008 and November 2024 at the Ophthalmology department in Pitié-Salpêtrière Hospital.
resultsWe identified 19 patients with suspected SO. Among them, 12 patients had confirmed SO. Mean follow-up duration was 12 ± 3 [1.5-23] years. sex ratio was 2:1 with 67% male patients. SO occurred within a mean 3.7 ± 4 years [0.25-27] years (median: 2.13 years), after the inciting event. Trauma and/or multiple intraocular surgeries in the inciting eye were present in all patients. Tocilizumab showed promising results in our cohort, with 2/3 patients achieving inflammation control for 4 and 8 years respectively, and no clinically significant side effects in all 3 patients. Anti-VEGF intravitreal injections (IVI) were added in case of associated choroidal neovascularization, intra-/periocular corticosteroids also played a key role in managing inflammatory macular edema.
conclusionManagement of SO has significantly evolved over the past decades, with new immunomodulatory or immunosuppressive approaches providing an improved tolerance profile and better clinical outcomes. Further studies with a greater number of patients are needed to determine which treatment strategies would be most optimal.
Indexed as
Identifiers
42771214What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.